Roche to present new OCREVUS (ocrelizumab) data in multiple
sclerosis and continued research into neuromyelitis optica spectrum
disorder at ECTRIMS 2022
- OCREVUS data will show
significant benefit on slowing disease activity and progression in
patients with treatment-naive early-stage relapsing-remitting
multiple sclerosis (RRMS)
- Largest pregnancy safety
data across anti-CD20 medicines for OCREVUS in multiple sclerosis
(MS)
- Nine-year safety data for
OCREVUS reinforces its favourable
benefit-risk profile
- New research demonstrates
impact of misdiagnosis and delay of starting treatment in
NMOSD
Basel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
today announced that new OCREVUS® (ocrelizumab) data and continued
research into neuromyelitis optica spectrum disorder (NMOSD) will
be presented at the 38th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) from 26-28
October 2022. These data include 35 abstracts, highlighting disease
activity and progression results in early-stage RRMS, pregnancy
outcomes from more than 2,000 women with MS and long-term safety
data for OCREVUS, as well as global NMOSD data exploring impact of
delayed treatment, clinical characterization of disease severity
and stability, and accurate identification of people living with
NMOSD through healthcare claims-based algorithms. Finally, the
design of a Phase III study evaluating the efficacy and safety of
satralizumab in Myelin Oligodendrocyte Glycoprotein
Antibody-associated Disease (MOGAD), a rare, chronic and
debilitating autoimmune disease primarily affecting the optic
nerve, brain and spinal cord, will be presented.
“Our aim is to enable people living with MS and NMOSD to
maintain life to the fullest. With over 250,000 people treated with
OCREVUS, we continue to see significant reductions in MS disease
progression balanced with favourable safety,” said Levi Garraway,
M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global
Product Development. “We are also focused on remaining unmet needs
– such as earlier diagnosis and treatment – which is critical to
ensure patients are receiving the most appropriate treatment.”
Multiple sclerosis (MS)Roche will present 29 MS
abstracts, including data from a two-year interim analysis of
treatment-naive, early-stage patients with RRMS from the open label
Phase IIIb ENSEMBLE study that will show the positive impact on
disease activity and progression when newly diagnosed patients are
treated with OCREVUS, and outcomes from the largest cumulative
pregnancy dataset for an anti-CD20 MS medicine in more than 2,000
women treated with OCREVUS. Long-term data from all OCREVUS
clinical trials in relapsing MS (RMS) and primary progressive MS
(PPMS) over nine years will reinforce the consistently favourable
benefit-risk profile of OCREVUS.
Neuromyelitis
optica spectrum disorder
(NMOSD)Roche will present five NMOSD
abstracts, including the development and testing of a healthcare
claims-based algorithm to identify people living with NMOSD.
Misdiagnosis of NMOSD is common and associated with a delay in
initiating maintenance therapy. This was highlighted in a study
looking to develop a clearer understanding of patient
characteristics, relapse severity and other drivers of treatment
choice.
The development of validated consensus statements on AQP4-IgG
seropositive NMOSD management will also be presented with a focus
on treatment recommendations including satralizumab; these
statements aim to optimise patient outcomes through informed
treatment decision making. The characterisation of disease severity
and stability in NMOSD will also be presented, with the aim of
integrating these in worldwide NMOSD clinical practice.
Roche will also present the study design from a Phase III study
that will evaluate the efficacy and safety of satralizumab in
MOGAD.
Follow Roche on Twitter via @Roche and keep up to date with
ECTRIMS 2022 news and updates by using the hashtag
#ECTRIMS2022.
Medicine |
Abstract title |
Presentation number
(Type) Presentation
date Time |
e-Posters available from 26 October at 8:00
CESTPoster presentations scheduled for 26 October
at 16:30-18:30 CEST unless indicated differently |
OCREVUS for
MS |
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for
the Treatment of Multiple Sclerosis |
0038 (Oral) 26 October14:49-14:56 CEST |
Treatment-Naive Patients With Early-Stage Relapsing-Remitting
Multiple Sclerosis Showed Low Disease Activity After 2-Year
Ocrelizumab Therapy, With No New Safety Signals; The Phase IIIb
ENSEMBLE Study |
P285 (Poster) 27 October13:20-13:25 CEST |
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in
Patients With Relapsing and Primary Progressive Multiple
Sclerosis |
P326 (Poster) |
An Interim Analysis of Efficacy and Safety Data in Black and
Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab
Treatment in the CHIMES Trial |
P686 (Poster) |
Demographics and Baseline Disease Characteristics of Patients With
Relapsing Multiple Sclerosis From Kenya Participating in the CHIMES
Trial |
EP1049 (e-Poster) |
The Patient Perspective on Family Planning Needs and Priorities in
Multiple Sclerosis: a Combined Quantitative and Qualitative
Research Study |
P077 (Poster) |
Blood Neurofilament Light Levels Predict Non-Relapsing Progression
Following Anti-CD20 Therapy in Relapsing and Primary Progressive
Multiple Sclerosis: Findings From the Ocrelizumab Randomised,
Double-Blind Phase 3 Clinical Trials |
P256 (Poster) |
Identification of Novel CSF Measures of Disease Activity and
Chronic Progressive Biology in MS: Results of the Ocrelizumab
Biomarker Outcome Evaluation Study (OBOE): A Randomised, Open-Label
Clinical Trial |
P449 (Poster) 27 October13:34-13:40 CEST |
Real-World Clinical and Economic Outcomes Among Persons With
Multiple Sclerosis Initiating First- vs. Second-Line Treatment With
Ocrelizumab |
EP1127 (e-Poster) |
Trends in the Use of Disease-Modifying Therapies in Pre-Pregnant
Women With Multiple Sclerosis in the United States: a Claims
Database Analysis |
P479 (Poster) 27 October17:00-19:00 CEST |
COVID-19 Vaccination Patterns and Outcomes Among Persons With
Multiple Sclerosis in the FlywheelMS Cohort |
EP1100 (e-Poster) |
Ocrelizumab in Patients With Early-Stage RRMS – Results From the
Phase IIIb ENSEMBLE Trial and the Matched Real-World NTD MS
Registry Cohort |
P771 (Poster) 27 October17:00-19:00 CEST |
Safety of Shorter Ocrelizumab Infusion Confirmed Over Multiple
Administrations: Results of the ENSEMBLE PLUS Substudy |
P739 (Poster) 27 October17:00-19:00 CEST |
Efficacy and Safety of Ocrelizumab is Maintained in Patients with
RRMS with Suboptimal Response to Prior Disease-Modifying Therapies:
4-Year NEDA Data from CASTING-LIBERTO |
P289 (Poster) |
Employment and Cognitive Improvements in Ocrelizumab-Treated
Patients With Relapsing-Remitting Multiple Sclerosis: 96-Week
CASTING Study Data |
P776 (Poster) 27 October17:00-19:00 CEST |
Cognitive Improvements in Ocrelizumab-Treated Patients with
Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study
Data |
P377 (Poster) |
Long-Term Efficacy and Safety of Ocrelizumab in Treatment-Naive
Patients With Early Relapsing Multiple Sclerosis: 7-year Data From
the OPERA Open-Label Extension Trials |
P723 (Poster) 27 October13:30-13:35 |
Eight-Year Analyses of Repeated Confirmed Disability Progressions
in the OPERA and ORATORIO Studies and Their Open-Label
Extensions |
P050 (Poster) |
Ocrelizumab Dose Selection for Treatment of Relapsing-Remitting
Multiple Sclerosis in Children and Adolescents: Preliminary
Pharmacokinetic, Safety and Efficacy Results From the OPERETTA 1
Study |
P444 (Poster) 27 October17:00-19:00 CEST |
Infusion-Related Reactions With Ocrelizumab in Relapsing Multiple
Sclerosis: Over 9 Years of Data From OPERA OLE |
P725 (Poster) 27 October 17:00-19:00 CEST |
SARS-CoV-2 Vaccination and COVID-19 Infections in People With
Multiple Sclerosis Treated With Ocrelizumab in the Prospective,
Multicenter, Noninterventional MuSicalE and CONFIDENCE
Studies |
P562 (Poster) 27 October 17:00-19:00 CEST |
SARS-CoV-2 vaccine-induced immune responses and breakthrough
infections in people with multiple sclerosis treated with
ocrelizumab |
P553 (Poster) 27 October17:00-19:00 CEST |
Severe COVID-19 Outcomes Following Vaccination in Persons With
Multiple Sclerosis: a Real-World Evidence Study |
P747 (Poster) 27 October17:00-19:00 CEST |
Longitudinal Study of Humoral and Cellular Responses to COVID-19
mRNA Vaccines With and Without 3rd (“Booster”) Dose in MS Patients
on Ocrelizumab: 24-Week Results From VIOLA (NCT04843774) |
EP1052 (e-Poster) |
Clinical and MRI Outcomes in Pediatric-Onset MS Patients on
Ocrelizumab and Fingolimod |
EP0995 (e-Poster) |
Floodlight in MS |
Assessment of Upper Extremity Function and Performance Fatigability
in Multiple Sclerosis Using Sensor-Based Features Derived From the
Smartphone-Based Pinching Test |
O144 (Oral) 28 October10:49-10:56 CEST |
Identification of Distinct Adherence Profiles for Smartphone
Sensor-Based Tests (Floodlight) in a Study of People With
Progressive Multiple Sclerosis (CONSONANCE) |
P123 (Poster) |
Remote Passive Monitoring in People Living With Progressive
Multiple Sclerosis During the COVID-19 Pandemic Shows a Measurable
Reduction in Daily Activity |
P522 (Poster) 27 October17:00-19:00 CEST |
A Prospective Study of the Feasibility of Smartphone-Based
Self-Monitoring to Characterise Cognitive and Neurological
Impairment in People With Multiple Sclerosis: Floodlight MS
MoreActive |
EP0886 (e-Poster) |
ENSPRYNG for NMOSD |
International, evidence-based Delphi consensus on the management of
AQP4-IgG seropositive NMOSD, with a focus on treatment
recommendations for eculizumab, inebilizumab and satralizumab |
P008 (Poster) |
Understanding treatment decisions in neuromyelitis optica spectrum
disorder: a global clinical record review with patient
interviews |
P412 (Poster) 27 October17:00-19:00 CEST |
Characterisation of disease severity and stability in neuromyelitis
optica spectrum disorder: a global clinical record review with
patient interviews |
P417 (Poster) 27 October17:00-19:00 CEST |
Development and Validation of a Claims-Based Algorithm to Identify
Patients with Neuromyelitis Optica Spectrum Disorder |
EP0911 (e-Poster) |
Baseline Characteristics of Initial Patients in the CorEvitas
SPHERES Registry for NMOSD |
P408 (Poster) 27 October 17:00-19:00 CEST |
satralizumab for MOGAD |
METEOROID: A Randomised, Double-Blind, Placebo-controlled,
Multicentre Phase 3 Study of Satralizumab in Patients with Myelin
Oligodendrocyte Glycoprotein Antibody-associated Disease |
EP1040(e-Poster) |
About OCREVUS
(ocrelizumab)OCREVUS is
the first and only therapy approved for both RMS (including RRMS
and active, or relapsing, secondary progressive MS [SPMS], in
addition to clinically isolated syndrome [CIS] in the U.S.) and
PPMS. OCREVUS is a humanised monoclonal antibody designed to target
CD20-positive B cells, a specific type of immune cell thought to be
a key contributor to myelin (nerve cell insulation and support) and
axonal (nerve cell) damage. This nerve cell damage can lead to
disability in people with MS. Based on preclinical studies, OCREVUS
binds to CD20 cell surface proteins expressed on certain B cells,
but not on stem cells or plasma cells, suggesting that important
functions of the immune system may be preserved. OCREVUS is
administered by intravenous infusion every six months. The initial
dose is given as two 300 mg infusions given two weeks apart.
Subsequent doses are given as single 600 mg infusions.
About ENSPRYNG
(satralizumab)ENSPRYNG,
which was designed by Chugai, a member of the Roche Group, is a
humanised monoclonal antibody that targets interleukin-6 (IL-6)
receptor activity. ENSPRYNG was designed using novel recycling
antibody technology which, compared to conventional technology,
allows for longer duration of the antibody and subcutaneous dosing
every four weeks.
Positive Phase III results for ENSPRYNG, as both monotherapy and
in combination with baseline immunosuppressive therapy, demonstrate
that IL-6 inhibition is an effective therapeutic approach for
neuromyelitis optica spectrum disorder (NMOSD). ENSPRYNG is
currently approved for NMOSD in 72 countries with further
applications under review with numerous regulators. Roche continues
to investigate ENSPRYNG in further indications including
generalised myasthenia gravis (gMG), Myelin Oligodendrocyte
Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune
Encephalitis (AIE).
ENSPRYNG was granted Breakthrough Therapy Designation for the
treatment of NMOSD by the FDA in December 2018 and designated as an
orphan drug for NMOSD in the United States, Europe, Russia and
Japan.
In addition, it has been designated as an orphan drug for gMG,
MOGAD and AIE (NMDAR).
About Roche in
neuroscienceNeuroscience is a major focus of
research and development at Roche. Our goal is to pursue
ground-breaking science to develop new treatments that help improve
the lives of people with chronic and potentially devastating
diseases.
Roche has both approved and investigational medicines across
multiple sclerosis, spinal muscular atrophy, neuromyelitis optica
spectrum disorder, myasthenia gravis, Alzheimer’s disease,
Huntington’s disease, Parkinson’s disease and Duchenne muscular
dystrophy. Together with our partners, we are committed to pushing
the boundaries of scientific understanding to solve some of the
most difficult challenges in neuroscience today.
About Roche Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world’s largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalised
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognising our endeavor to pursue a long-term perspective in
all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the thirteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
Roche Group Media RelationsPhone: +41 61 688
8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 61 687
41 47 |
Nathalie AltermattPhone: +41 61
687 43 05 |
Karsten KleinePhone: +41 61 682
28 31 |
Nina MählitzPhone: +41 79 327 54
74 |
Dr.
Barbara von SchnurbeinPhone: +41 61 687 89 67 |
Sileia Urech Phone: +41 79 935 81
48 |
Roche Investor Relations
Dr.
Bruno Eschli Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com |
Dr.
Sabine BorngräberPhone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com |
Dr.
Birgit MasjostPhone: +41 61
68-84814e-mail: birgit.masjost@roche.com |
Dr.
Gerard Tobin Phone: +41 61 68-72942 e-mail:
gerard.tobin@roche.com |
Investor Relations North America
Loren
Kalm Phone: +1 650 225 3217 e-mail:
kalm.loren@gene.com |
|
- 19102022_MR_ocrevusECTRIMS_en
Roche (LSE:0QQ6)
過去 株価チャート
から 3 2024 まで 4 2024
Roche (LSE:0QQ6)
過去 株価チャート
から 4 2023 まで 4 2024